Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Phase 2 Terminated
7 enrolled 10 charts
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Phase 1 Terminated
272 enrolled
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Phase 2/3 Terminated
130 enrolled 13 charts
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Phase 1/2 Terminated
13 enrolled 24 charts
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
Phase 1/2 Terminated
34 enrolled
Safety Study of SEA-CD40 in Cancer Patients
Phase 1 Terminated
159 enrolled
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Terminated
102 enrolled 51 charts
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Phase 3 Terminated
492 enrolled 16 charts
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Phase 1/2 Terminated
83 enrolled 31 charts
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Phase 1 Terminated
9 enrolled 12 charts
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Phase 3 Terminated
149 enrolled 17 charts
A Safety Study in Participants With Advanced Solid Tumors
Phase 1 Terminated
234 enrolled 23 charts
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
Phase 2 Terminated
3 enrolled 9 charts
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Phase 1 Terminated
5 enrolled
Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer
Phase 1 Terminated
7 enrolled
PM-01
Phase 1 Terminated
3 enrolled
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
Phase 3 Terminated
100 enrolled
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
Phase 2 Terminated
60 enrolled